The hepatitis B virus (HBV) is a double-stranded DNA virus [1] which is generally spread by intimate contact or percutaneously in infected blood via contaminated needles or tubing. In typical acute hepatitis B, hepatitis B surface antigen (HBsAg) is the first marker of infection detectable in serum [2] . By the time the Only a minority of infected immunocompetent adults fail to recover from acute hepatitis B and develop chronic hepatitis B. In these individuals, about 5% of acutely infected persons, HB5Ag persists in serum and anti-HBs fails to appear. By contrast, patients acquiring HBV infection while on chronic hemodialysis have a much higher likelihood than immunocompetent persons of developing chronic hepatitis B, Two phases of chronic HBV infection can be identified. In the early months and years of chronic HBV infection, viral replication persists and is manifested by high levels of HBV DNA and HBeAg in serum. This "replicative" phase is often accompanied by necroinflammatory changes in the liver and elevated serum aminotransferase levels.
minute concentrations of HBV DNA may remain detectable by polymerase chain reaction for variable periods of time [2] .
Hepatitis B and hemodialysis Viral hepatitis was recognized as a major problem in hemodialysis units by the late 1960s in both Europe and North America [3] [4] [5] . Between 1967 and 1971, the European Dialysis and Transplant Association reported annual incidence rates for HBV infection of 5 to 10% in patients undergoing chronic hemodialysis [6] .
Recognition of the role of HBV as a cause of hepatitis in hemodialysis units dates back more than 20 years. Garibaldi et al [5] reported on a prospective study of viral hepatitis in 65 hemodialysis units in the United States between 1967 and 1970. Although testing for HB5Ag was only introduced in the latter years of the study, the authors observed that 9 (7%) of 136 patients whose case records were extensively reviewed died of HBV-related liver disease. A point-prevalence study of 15 dialysis units in which 583 patients and 451 medical personnel were screened for serologic evidence of HBV infection from 1972 to 1973 identified HBsAg in the serum of 16.8% of the patients and 2.4% of the medical staff. Antibody to HBsAg was detected in 34.0% of patients and 31.3% of staff [7] . This study also demonstrated that serologic evidence of HBV infection was correlated with both the number of units of blood transfused and, especially, the length of time on chronic hemodialysis. A survey of 750 American dialysis centers undertaken by Alter and colleagues at the Centers for Disease Control in (CDC) [8] found that, in 1976, the overall prevalence of HBs antigenemia was 7.8% among 22,876 patients and the annual incidence rate of HBV infection was 3.0% among 33,875 tested individuals. A repeat survey in 1980 demonstrated a significant decline in the prevalence of HBV infection to 3.8% and in the incidence of HBV infection to 1%, presumably because of the introduction of infection control measures (see below).
Because of these and similar reports [9] , in 1977, the CDC issued recommendations for controlling the spread of HBV in hemodialysis centers [10] . These recommendations included segregation of HBsAg-positive patients from HBsAg-negative patients, the use of dedicated dialysis machines for HB5Ag-positive patients, and regular serologic screening for HBsAg and anti-HBs, in addition to routine cleaning and disinfection procedures. In a follow-up study by Alter and colleagues from the CDC on the impact of these recommendations on HBV infection in 1, 255 hemodialysis units [11] , a significant decline in HBsAg seropositivity among patients and staff was observed between 1976 and 1982. The incidence of HBsAg seropositivity in patients declined from 3.0% in 1976 to 0.5% in 1982, and the incidence in staff decreased from 2.6% to 0.5% during those years. Clearly, the CDC recommendations had a considerable impact on reducing Disease progression related to active viral replication [18] liver biopsies [16, 17] Abbreviations are: HBV, hepatitis B virus; HD, hemodialysis.
the problem of HBV transmission in hemodialysis units in the United States. Indeed, in the latest of a series of comprehensive annual surveys of U.S. hemodialysis units by Alter and colleagues from the CDC [121, the annual incidence of HBV infection among patients had declined further to 0.1% in 1989, with a prevalence of 1.4%, and the annual incidence among staff members had declined to 0.1%, with a prevalence of 0.3%. It is particularly noteworthy that the major decline in the HBV infection rate between 1976 and 1980 antedated the widespread availability of HBV vaccination.
Improved control of the spread of HBV within hemodialysis units has probably been less dramatic in other countries where there is a higher prevalence of HBV in the general population. In a study of renal transplant recipients, Degos et al noted that the prevalence of HBV infection in hemodialysis units in France was 46.2% and 15.8%, respectively, before and after the introduction of control measures to prevent the spread of HBV [131. In hemodialysis units in other areas endemic for HBV, including Israel [14] and Saudi Arabia [15] , high incidence rates for HBV infection continue to be reported.
Besides serving as a reservoir for the spread of HBV to other patients and medical staff, patients chronically infected with HBV are at risk of developing decompensated liver disease. A high rate of chronicity as well as progression of liver disease have been described in patients on HD who become infected with HBV (Table 1) . Furthermore, active viral replication promotes histological progression [16] [17] [18] .
The high risk of chronicity following infection with HBV in patients on hemodialysis has been attributed in part to depressed cell-mediated immunity. Lee et al studied lymphoproliferative responses in hemodialysis patents with and without HBV infection as well as HBV-infected controls without renal disease, and observed depressed lymphoproliferative responses to phytohemagglutinin and concanavalin A only in the HBV-infected hemodialysis patients [19] . These results suggest impairment of cellmediated immunity despite a normal number of T cells and an increased CD4ICD8 ratio in all the hemodialysis patients.
Hepatitis B vaccination
With the widespread application of HBV vaccination, initially with plasma-derived and more recently with recombinant vaccines containing HBsAg, it has become apparent that patients on chronic hemodialysis have a suboptimal antibody (anti-HBs) response compared to the general population. In an early trial, Stevens et al reported that more than 80% of 79 hemodialysis patients developed anti-HBs following two or three doses of a plasma-derived HBV vaccine [20] . However, Crosnier et al demonstrated that the response rate and protective efficiency of vaccination was lower in patients than staff in French hemodialysis units [21] : only 26 of 43 (60%) hemodialysis patients developed anti-HBs titers >10 mIU/ml (a level felt to provide protection). Vaccine responders tended to be female and less than 50 years old. In contrast, 93% of staff members developed protective antibodies in this study. In addition, the level of anti-HBs was 20 -fold higher in the medical staff responders than the hemodialysis responders [22] . A number of host factors have been identified that contribute to nonresponse to the HBV vaccine both in normal and dialysis patients. These include older age, obesity, and possession of the major histocompatibility complex haplotype HLA-B8, SCOI, DR3 [23, 24] .
A variety of approaches have been tried to enhance the response to HBV vaccination in hemodialysis patients. The yeastderived vaccine is not more immunogenic than the plasmaderived vaccine, and nonresponse to one type of vaccine is generally not overcome by vaccination with the alternative type [25] . Kohler and colleagues demonstrated anti-HBs seroconversion following a fourth dose of plasma-derived vaccine in 16 of 43 (37%) initial nonresponders; however, in nine such responders (56%) the initial response to vaccination had actually been transient, not absent [26] . Bruguera and colleagues, using a yeast-derived HBV vaccine, found that a higher dose (40/j.g rather than 20/jg) and a schedule of four injections at 0, 1, 2, and 6 months was superior to a regimen of 0, 1,2, and 12 months; both regimens were more efficacious in producing an adequate immune response than a three-injection schedule [27] . Inclusion in the vaccine of a more extended portion of the HBV genome containing the pre-S2 (as well as the HBsAg) protein may increase the response rate to vaccination in hemodialysis patients [25] , and the appearance of anti-pre-S2 antibodies in vaccinees has been shown to correlate with high anti-HBs titers [28] . The response rate to HBV vaccination in this population has also been reported to increase with co-administration of immune modulators such as gamma interferon [29] and thymopentine [30] . Use of these and other novel approaches, such as adjuvant interleukin-2, are under study [25, 31j. Even following an adequate anti-HBs response to vaccination, hemodialysis patients appear to have a poor ability to maintain protective antibody levels. Fleming and colleagues [32] Patients with persistent anti-HBs levels typically were younger and had higher initial anti-HBs levels than those in whom anti-HBs levels became undetectable. Of particular note, four cases of acute hepatitis B in hemodialysis patients, despite the previous development of apparently protective anti-HBs levels, were described by Stevens et al [34] . Anti-HBs levels had declined by the time of infection in three cases and may have been negated by therapeutic immunosuppression in the fourth patient, who had undergone renal transplantation.
Perhaps the most important reason for lack of protection by J-IBV vaccine in hemodialysis patients is lack of application. A national surveillance of dialysis units in the U.S., undertaken in 1989, found that only 19% of susceptible patients and 55% of staff members had been vaccinated against HBV [12] . Despite its limitations, HBV vaccination is useful in the hemodialysis population. Still, the recommendations of the CDC concerning control measures against HBV in hemodialysis units have stood the test of time and for the foreseeable future will remain the mainstay of controlling HBV in this setting. It is possible that vaccination of patients before the development of advanced chronic renal disease will further increase the effectiveness of measures to limit the spread of HBV in the dialysis setting [25] .
Hepatitis B and renal transplantation The effect of renal transplantation (RT) and associated therapeutic immunosuppression on the course of HBV-related liver disease has been a subject of debate in the literature for many years [35] [36] [37] [38] . Reports from the early 1970s suggested that HBsAg seropositivity was associated with serious hepatic dysfunction in transplant recipients [35, 37, 38] .
In a detailed prospective study of 22 HBV-infected RT recipients, Parfrey et a! documented progression of liver disease over a mean follow-up of 83 months [39] . Cirrhosis developed in 12 of 20 (60%) patients who did not have cirrhosis on initial biopsy. Eleven of the 20 (55%) died of liver disease. In contrast, 10 HBV-infected patients on chronic hemodialysis, followed over a comparable period of time, experienced no evidence of progressive hepatic dysfunction or death from liver disease. Of particular note was that three of the deaths were due to primary hepatocellular carcinoma, presumably because of the increased rate of cirrhosis as also noted by others [40, 41] (Table 2) .
The effect of RT on HBV viral activity has been described by Dusheiko et al [42] and others [43] . Increased replication with reappearance or increase in serum HBV DNA levels and HBeAg occurs as well as even reappearance of serum HBsAg following apparent clearance of previous HBV infection. Rao On the basis of these and similar recent studies [35-45], a number of conclusions can be made: HBV infection is associated with significant hepatic dysfunction in many RT recipients. Moreover, RT accelerates the progression of liver disease, and at least some HBV-infected RT recipients experience increased morbidity and even mortality as a consequence of HBV infection. Because of these observations, some workers have questioned the wisdom of offering RT to HBV-infected patients. Harnett and colleagues have provided additional information on the outcome of HBVinfection in RT recipients compared to a group of patients on hemodialysis [17, 46] . Thirty-one HBV-infected patients were followed for a mean of 55 months following infection. Whereas only one of the 12 deaths in the dialysis group could be attributed to liver disease, 8 of 14 (57%) deaths in the RT group were related to liver disease. The excess mortality rate in the RT group persisted when adjusted for a longer period of follow-up in the RI' group. On the basis of these findings, the authors cautioned against RT in HBV-infected patients and implied that hemodialysis may offer a better long-term outcome in such patients.
Friedlaender and colleagues from Israel have offered a less gloomy view of RT in HBV-infected patients based on their personal experience as well as a comprehensive review of the literature [47] . They suggest that most prior reports had selected patients who already had significant hepatic dysfunction at the time of RT or who had acquired HBV following RT and thus might have been expected to deteriorate due to high-dose postoperative immunosuppression. Friedlaender also described the severe nature of acute HBV infection occurring post-RT in 4 of 200 RT recipients [47] . Two of the 4 patients died of "acute yellow atrophy," presumably due to HBV, one patient developed chronic hepatic dysfunction, and one patient seroconverted to anti-HBs. Immunosuppressive agents are clearly permissive for HBV replication in RT recipients. As demonstrated by Dusheiko and others [42, 49] , RT is associated with reactivation of HBV replication. Degos and colleagues also demonstrated viral reactivation and/or increased replication in HBsAg-positive patients post-RT [13] . In addition, they described a subset of patients without HBsAg or HBV DNA in serum before RT but with HBV DNA detected by dot-blot hybridization in serum following RT, a finding which suggests that immunosuppression amplifies even minimal residual HBV replication. In many of this subset, hepatic tissue contained HBV DNA, particularly if there was histological evidence of chronic hepatitis at the time of RT. More recently, the same group has described the reappearance of HBsAg following RT in a patient who had had acute HBV infection 10 months prior to RT and then developed an anti-HBs response [50] . This patient, in fact, had HBV DNA detectable in serum by PCR pre-RT, suggesting that resolution of acute infection had been relative rather than absolute.
The deleterious effect of therapeutic immunosuppression on the course of HBV infection has been recognized in a number of other clinical settings. Reactivation of HBV infection has been well described in HBsAg-positive patients receiving cytotoxic cancer therapy, and has led to death from acute liver failure in some patients [51, 52] . Analogous to RT, orthotopic liver transplantation in many HBV-infected patients is associated with reinfection of the liver graft followed by rapidly progressive liver disease with reduced survival of both graft and patient [531 Absence in serum of hepatitis B e antigen and/or HBV DNA in RT recipients may decrease the likelihood of hepatic decompensation, but does not preclude a poor outcome due to worsening of liver disease [54] . The advent of PCR testing has demonstrated that even a minute viral level pre-transpiantation can be associated with HBV reinfection of the liver graft [53] .
Therapeutic immunosuppression may enhance HBV replication via a number of mechanisms. The HBV genome contains a glucocorticoid-responsive element that, when activated, may increase the transcription of HBV genes. In a transgenic mouse model of HBV, in which HBsAg is incorporated into the host genome, HBsAg production is in fact regulated by glucocorticoids as well as sex hormones [55] . Cyclosporine may also have direct effects on HBV replication. The woodchuck hepatitis virus, a member of the hepadnavirus family like human HBV, undergoes increased replication when exposed to cyclosporine [56] ; the mechanism of enhanced viral replication is uncertain. It is likely that impairment of host responses contributes to enhanced hepadnavirus replication related to therapeutic immunosuppression.
The observation has been made by Degos and colleagues that the development of extensive liver fibrosis and ultimately cirrhosis in RT recipients with HBV-related chronic hepatitis occurs in the absence of extensive hepatocellular necrosis or inflammatory changes [57] . This lack of a marked inflammatory response has also been described in other HBV-infected immunocompromised hosts, including orthotopic liver transplant recipients [58] and patients with the acquired immunodeficiency syndrome [59] , and may account, at least in part, for the lack of elevated serum aminotransferase levels often observed in RT recipients and other immunocompromised hosts with chronic hepatitis B [60, 61] .
The effect of HBV infection on graft survival following RT remains controversial. In a study of RT recipients, London and colleagues in Philadelphia reported that the presence of HBsAg in serum delayed renal graft rejection, whereas anti-HBs was associated with early graft rejection, particularly if the donor was male [62] . In contrast, Chatterjee et al detected no discernible effect of HBV infection or immunity on renal graft survival [36] . In an astute analysis of the study reported by Degos and colleagues [13] on HBV replication and reactivation following RT, Dienstag attempted to reconcile some of these discrepancies [63] . He observed that collectively over a two to three year period renal graft survival was 82% in HBsAg-positive patients but only 61% in HBsAg-negative patients. However, in those patients who were HBsAg-negative in serum but HBV DNA-positive in hepatic tissue, renal graft survival was intermediate at 75%. He concluded that reported differences in the effects of HBsAg on graft survival may have reflected the unrecognized presence of HBsAg negative! HBV DNA-positive RT recipients in whom graft survival is superior to that of truly HBV-negative recipients.
A number of approaches have been tried to arrest the progression of HBV infection in RT recipients. Several investigators have reported on attempts to reduce therapeutic immunosuppression for this purpose without convincing benefit [64, 65] .
Others have reported on the introduction of cyclosporine therapy [66, 67] . In a histologic study of liver disease in HBsAgpositive RT recipients receiving cyclosporine over a mean follow-up of 43 months, Stempel and colleagues concluded that the liver disease was generally mild and speculated that this was the result of the reduction in doses of azathioprine and prednisone possible when cyclosporine was added to the immunosuppressive regimen [68] . As discussed above, corticosteroids are recognized to worsen HBV-related chronic liver disease [69] , and attempts to reduce the dose of prednisone following RT are probably appropriate.
Recombinant alpha-interferon has demonstrated efficacy in the treatment of chronic hepatitis B in non-transplanted immunocompetent hosts and leads to loss of HBeAg in up to 50% of treated patients with associated improvement in liver histology [70] and in many responders ultimate resolution of HBV infection in the several years following therapy [71] . However, because of the immunomodulating effect of interferon, there is at least a theoretical risk that interferon may enhance graft rejection [72] . As discussed later, use of interferon to treat HBV infection in RT recipients is probably best reserved for controlled clinical trials until more information about the risk/benefit ratio is available.
Recommendations regarding renal transplantation in HBV-infected patients
Because of the effective control of HBV in hemodialysis units, the number of HBV-infected patients undergoing evaluation for RT will continue to decline. At present, decisions about RT in HBV-infected patients should be based on both the severity of liver histology and the results of testing for markers of replication in serum, including HBV DNA and HBeAg. Nevertheless, the absence in serum of HBV DNA or HBeAg prior to RT does not preclude reactivation of HBV infection following RT under the influence of immunosuppression. Studies in North America [39, 44, 46] have shown that patients with severe chronic active hepatitis or established cirrhosis on liver biopsy are at particular risk of hepatic decompensation following RT, and in these individuals RT should be avoided, especially if markers of active viral replication are present. In countries other than the US with a higher prevalence of HBV in the general population, many infected patients will continue to enter the dialysis and transplant pool, and even within the United States, large-scale migration from Southeast Asia, an area endemic for HBV, will undoubtedly continue to present physicians with a dilemma about the wisdom of transplanting infected patients.
Given the generally favorable outcome of many patients, chronically infected with HBV, with less histologically severe liver disease, such as chronic persistent hepatitis, RT should not be precluded in these patients. However, all patients infected with HBV must be cautioned that even histologically mild disease has the potential to deteriorate under the influence of immunosuppression. It is hoped that future developments in antiviral therapy will diminish the hazards of RT in patients with HBV infection [73] .
Hepatitis D (delta hepatitis) Hepatitis D virus (HDV), also known as the delta agent, is only found in the presence of HBV infection. An RNA virus, HDV requires HBV to complete its replicative cycle [74] . HDV infection may occur simultaneously with acute HBV infection (coinfection) or may be acquired during the course of chronic HBV infection (superinfection). The clinical significance of HDV is its ability to increase the severity of HBV infection; unlike HBV, HDV is almost invariably associated with clinically important hepatic dysfunction. In North America, HDV infection is most commonly found among intravenous drug abusers who share contaminated needles and syringes. Elsewhere in the world, HDV is endemic in certain tropical and subtropical areas with high prevalences of HBV infection.
Routine serologic diagnosis of HDV infection is currently based on detection of circulating antibody to HDV antigen (anti-HDV) [75] . In acute HDV infection, anti-HDV levels may be of low titer and anti-HDV may disappear with resolution of infection. In chronic HDV infection, anti-HDV levels are persistent and of high titer.
Fortunately, HDV infection generally has not been a major problem in hemodialysis and RT programs. A number of groups specifically have reported the absence of HDV infection in HBV-infected RT recipients [13, 39, 76, 77] . Nevertheless, HDV infection should be considered in any patient with rapidly deteriorating liver disease due to HBV. Degos and colleagues in Clichy described delta superinfection as a rare event in RT recipients [57] . Previously, they had reported three cases of fulminant hepatitis occurring among 300 RT recipients followed from 1972 to 1983 [78] ; in two of these three cases, direct staining of liver tissue identified delta antigen, implicating HDV infection.
Hepatitis C
The hepatitis C virus (HCV), an RNA virus [79] , is the agent responsible for most, if not all, cases of transfusion-associated hepatitis, as well as many cases of sporadic non-A, non-B (NANB) hepatitis occurring in individuals with no obvious parenteral exposure to HCV. HCV infection is characterized by a high rate of chronicity with a propensity to insidious progression to cirrhosis and an increased risk of subsequent hepatocellular carcinoma. Since identification of HCV was relatively recent, serologic tests are still in evolution. First-generation tests, initially a radioimmunoassay and then an enzyme immunoassay, detected antibody to C100-3, a recombinant polypeptide expressed from the portion of the genome encoding non-structural proteins [80] . With firstgeneration tests, detection of antibody to C100-3 (anti-HCV) was delayed for up to several months after acute HCV infection and never developed in 30 to 40% of patients with apparently resolving acute hepatitis C [81] . In addition, anti-HCV was not detectable by first-generation ETA in up to 20% of well-pedigreed cases of transfusion-associated hepatitis despite the detection of HCV RNA in serum by use of PCR [81] . Because of these limitations and concerns about the nonspecificity of the first generation tests, second-generation tests, which incorporate a wider selection of HCV-related epitopes from regions of the genome encoding both structural and nonstructural peptides, have been introduced [82] . The additional epitopes are C22-3, a nucleocapsid core protein, and C200, a composite of C100-3 and C33, two peptides encoded by the nonstructural region. The diagnosis of HCV infection is now possible up to three months earlier with second-generation testing than with first-generation testing. Moreover, the sensitivity of confirming HCV as the cause of chronic NANB hepatitis is enhanced by 10 to 20% [82] . At present, routine diagnosis of HCV infection is based on second-generation anti-HCV testing. The recombinant immunoblot assay (RIBA) which also incorporates several HCV-related antigens has been introduced into routine diagnostic use as a supplementary test which enhances specificity of second-generation tests [2] . Although available experimentally, detection of HCV RNA by PCR and detection of 1gM anti-HCV
are not yet used routinely in clinical practice. A recent report highlights the limitations of even second generation serological tests for HCV in patients on chronic dialysis [83] . Twenty-eight (8.2%) of 340 patients tested with ELISA positive. However, an additional eight patients were viremic by PCR indicating a high false-negative rate for detection of HCV infection by serology alone. The branched chain DNA test which allows quantitative serum HCV RNA detection is currently undergoing clinical assessment [84] . Although significantly less sensitive than PCR, it is a reliable and reproducible technique to detect viremia. It seems likely in the future that diagnosis of HCV infection will include demonstration of viremia rather than detection of anti-HCV antibodies alone.
Role of hepatitis C in liver disease associated with chronic renal failure
After the introduction of diagnostic testing for HBV, it rapidly became apparent that most liver disease in patients undergoing HD or RT was not related to HBV. Despite the control of HBV infection in dialysis units, hepatic dysfunction continued to occur frequently [85, 86] . Bruguera and colleagues, reporting from Barcelona in 1985, ascribed episodes of acute hepatitis to "NANB hepatitis" by excluding HBV infection in 20 of 27 [74%] cases [87] . In 14 cases (70%) NANB hepatitis became chronic. Prior to the identification of HCV, similar conclusions about the importance of NANB hepatitis as a cause of hepatic dysfunction in RT recipients had been reached by LaQuaglia et al reporting from Boston in 1981 [88] . Hepatic dysfunction developed in approximately 10% of their 405 patients undergoing RT between 1970 and 1980, and in two thirds of the cases, a diagnosis of "NAN B hepatitis" was made. Others had also made similar observations about the importance of non-HBV related liver disease in RT recipients [89] .
Subsequently, diagnostic testing for anti-HCV by first-generation ELISA confirmed the importance of HCV infection as a cause of hepatic dysfunction in hemodialysis populations [90] [91] [92] .
Esteban et a! from Spain reported that 8 of 42 (19%) HD patients
were anti-HCV-positive [90] . Comparable rates of anti-HCV seropositivity were reported from other centers [91, 92] . As suggested by older studies [60, 61] , chronic viremia not associated with biochemical evidence of hepatic dysfunction is common in this population of patients [83, 94] . As noted above [83] , serological diagnosis in this population is limited by lack of sensitivity [93, 94], although an anti-HCV seropositivity by second generation testing is usually predictive of viremia [94] . An unresolved issue regarding HCV infection in HD units is whether HD per se is a risk factor for transmission or whether the high prevalence of anti-HCV seropositivity reflects acquisition of HCV from other exposures. Zeldis et al observed that lack of a history of intravenous drug abuse, absence of multiple blood transfusions, and negative serologic testing for current or previous HBV infection were highly predictive of the absence of HCV infection, suggesting that HD per se was not a risk factor for HCV infection [91] . In contrast, a number of other investigators found a correlation between the length of time on HD and the risk of HCV infection [95] [96] [97] . Five (0.8%) of 590 patients on chronic HD followed for one year developed de novo HCV seroconversion preceded by viremia. At least one and possibly three of these patients had no exposure to blood products for at least one year prior to onset of HCV infection [98] . Genomic sequencing of HCV isolates from three patients who developed anti-HCV antibodies while on chronic HD were identical in a Swedish study [99] . These patients were all dialyzed on the same shift but not the same machines. This strongly suggests nosocomial spread within the unit, as do other recent reports [100] . Further circumstantial evidence of HD as a possible risk factor for HCV infection is the finding of a lower prevalence of HCV seropositivity in patients maintained on chronic peritoneal dialysis. Chan, Lok and Cheng, reporting from Hong Kong, found in 130 RT recipients anti-HCV seropositivity in 15.4% and 2.2% of patients who had previously received chronic HD and PD, respectively, although the latter group had less requirement for blood products as a potential explanation [101] . With the marked reduction of transfusion requirements in the HD population since the introduction of erythropoietin, it may be possible to further address this issue in non-transfused HD and PD patients. Screening of blood products over the last several years for HCV infection has been reported to also reduce the prevalence of infection in HD units, from 43.6% to 21.2% in a French unit [102] . Four new cases of anti-HCV seroconversion occurred over a two month period in this unit in patients sharing the same dialysis machine implying nosocomial spread. Chiaramonte et al described an outbreak of acute NANB hepatitis in Italy occurring among patients undergoing HD on dialysis machines without completely disposable dialysate circuits [103] . Switching patients with acute hepatitis to machines with completely disposable circuits appeared to abort the spread of HCV within the unit, suggesting that the outbreak of hepatitis had been facilitated by the dialysis system and again providing evidence for transmission of HCV by HD. The clinical consequences of HCV infection in HD patients are probably more severe than originally appreciated. Studies performed before the identification of HCV had indicated that non-HBV related hepatic dysfunction was linica1ly mild in patients with chronic renal failure [104] . Caramelo arid colleagues from Spain have more recently reported their observations in patients on chronic HD with HCV infection [1051. Thirty-three patients underwent liver biopsy. Twenty (60%) of the biopsies showed evidence of injury consistent with chronic viral hepatitis, including three cases of cirrhosis complicated by hepatocellular carcinoma in one. Clinical and biochemical features were unable to predict the severity of histological injury in the study. Although HCV typically has an indolent progression, cirrhosis and primary liver cancer are possible outcomes as this study illustrates. Biopsy is the most accurate way to assess severity of liver injury. Hepatitis C and renal transplantation As in the HD population, a high frequency of NANB hepatitis has been recognized for many years in RT recipients [88, 89] . However, the prognosis of non-HBV related liver disease in RT recipients was thought to be better than that of HBV-related liver disease [44] . Once diagnostic testing for HCV became available, a number of reports confirmed that anti-HCV seropositivity was indeed common in RT recipients.
Using the first-generation anti-C100-3 ELISA test, Roth and colleagues from Miami retrospectively tested stored sera from 596
HBsAg-negative RT recipients and found that 180 (30%) were anti-HCV positive at the time of transplantation [106] . Of note, at one year follow-up the frequency of anti-HCV seropositivity had decreased to 22%, implying that at least some of the initially positive anti-HCV results may have been falsely positive and/or that therapeutic immunosuppression suppressed production of anti-HCV. Chan and colleagues from Hong Kong, reporting on the use of PCR to detect HCV RNA in addition to anti-HCV testing in 186 RT recipients, found HCV RNA in 22 (12%) patients, including 4 who were negative for anti-HCV by a second-generation anti-HCV antibody test [107] . Seventy-five percent of their patients with a clinical diagnosis of chronic "NANB" hepatitis had evidence of HCV infection. In this study, loss of anti-HCV seropositivity after RT was not observed, presumably because a second-rather than a first-generation antibody test was used. In this as in other studies of HCV infection in RT recipients, normal serum aminotransferase levels were observed in many patients with HCV infection. As in the HD population, serological diagnosis, even with second-generations tests, fails to detect some cases of HCV infection discovered by PCR [108] .
A number of studies have addressed the impact of RT on the course of HCV infection. This issue is complicated by the undoubted inclusion of patients who acquired HCV post-RT via transfusion of HCV-infected blood products before screening for anti-HCV was available. Roth et al observed no differences in patient and graft survival over a 10-year follow-up in anti-HCVpositive patients with and without biochemical evidence of hepatitis [106] . Pol and colleagues from Paris performed liver biopsies on 140 HBsAg-negative RT recipients either at the time of RT or during subsequent follow-up [108] ; 23.6% of the patients were anti-HCV-positive by first-generation ELISA. Although the presence of anti-HCV was associated with histologic evidence of liver injury in many patients, no differences in graft or patient survival were observed in the anti-HCV positive patients compared to anti-HCV-negative patients regardless of whether HCV was acquired pre-or post-RT. However, given the typically insidious progression of chronic hepatitis C over decades rather than years, a longer follow-up may be required to exclude an increase in mortality in HCV-infected RT recipients.
A recent study by Rao and colleagues in Minneapolis has
suggested that the severity of liver disease as assessed by biopsy provides useful prognostic information in RT recipients [109] . After a mean follow-up of 5.7 years, approximately one-third of the patients with early chronic active hepatitis and nearly twothirds with advanced chronic active hepatitis experienced clinical deterioration with the development of cirrhosis and, in some cases, death due to liver disease. The majority of patients with progressive liver disease were infected with HBV, but some of the liver-related deaths occurred in patients infected with HCV. Moreover, serum levels of HCV RNA have been found to increase post-RT [110] . Therefore, on the basis of the available data, evidence of severe chronic active hepatitis or cirrhosis on liver biopsy should probably be a relative, if not absolute, contraindication to RT, irrespective of the cause of liver disease. As is typical in patients with end-stage renal disease clinical and biochemical parameters of liver disease appears insensitive markers of histological severity [110] . Other factors can contribute to the severity of HCV-related liver injury. These include concomitant alcohol abuse as well as infection by an HCV strain with greater pathogenicity [111] . At least six different genotypes of HCV exist. An increasing literature suggests that disease progression and interferon responsiveness are to a significant degree determined by HCV genotype. Although a number of methods of HCV genotyping have been described positive, diagnostic typing is not routinely available. In the future, however, part of the prognostic profile in RT candidates with HCV infection may well include genotyping.
HCV transmission by organ donation
A number of reports have drawn attention to the apparent transmission of HCV by organs from infected donors. Pereira observed hepatic dysfunction attributable to HCV in 14 of 29 (48%) recipients of a variety of organs from HCV-infected donors [112] . Although the interpretation of the data has been questioned [113] , subsequent studies employing PCR to detect HCV RNA have suggested that transmission of HCV occurs in at least some recipients of organs from HCV seropositive donors and that transmission is inevitable if the donor is viremic [114] . Exclusion of viremic donors would decrease but not eliminate HCV transmission in the setting. Although the long-term consequences of infection with HCV via an infected donor organ are unresolved [116] , the use of organs from anti-HCV seropositive donors should probably be restricted to life-threatening circumstances, particularly because RT recipients, unlike liver transplant candidates, have the option of continuing chronic dialysis if transplantation needs to be deferred because a suitable donor is not available [117] . Although the course of HCV generally post-RT appears indolent there are clearly individual patients with poor outcomes due to HCV acquisition from donor organs as described by Pereira et al [112] . On the basis of the observation that reinoculation of chimpanzees with homologous as well as heterologous strains of HCV causes exacerbations of clinical hepatitis, transplantation of organs from HCV seropositive donors to seropositive recipients may also pose a risk to the recipient [118] . The impact of HCV viremia in the absence of biochemical evidence of liver injury on patient survival also remains uncertain [119] . In summary, increasingly the literature suggests that use of the HCV-positive donor frequently results in HCV transmission and that at least some patients suffer adverse outcomes as a result. Even though HCV typically takes many years to produce hepatic decompensation the occurrence of subfulminant liver failure in individual recipients as reported by Pereira et al [112] and others (G. Danovitch, personal communication) is a cogent argument against the use of anti-HCV seropositive donors on ethical grounds. may make demonstration of adverse effects of RT difficult [106, 110] Abbreviations are: HCV, hepatitis C virus; HBV, hepatitis B virus; RT, renal transplantation.
Role of antiviral therapy in recipients of renal transplants Alpha-interferon has well documented efficacy in the treatment of chronic hepatitis B [70] and C [120] in immunocompetent hosts. Unfortunately, detailed information is not available about a possible role for alpha-interferon in the treatment of chronic viral hepatitis in RT recipients. However, when alpha-interferon was used in high doses as prophylaxis against cytomegalovirus and herpes virus infections in RT recipients, a marked increase in the frequency of acute graft rejection resulted [121] , although lower doses of interferon had previously been used without increased rates of graft rejection in RT recipients [122] . Alpha-interferon in the usual dose used to treat chronic HCV was well tolerated and efficacious in a group of HD patients [1231. However, in a group of 13 RT recipients treated with standard doses of interferonalpha for chronic viral hepatitis, two patients experienced deterioration of graft function. In one ease this was felt to be due to active chronic rejection and in the other acute tubular necrosis. Overall, serum aminotransferases decreased during therapy but the response was not sustained once therapy was stopped and side effects were common [124] . Thus, at present use of alphainterferon is probably best reserved for controlled trials of antiviral therapy in RT recipients with chronic viral hepatitis. It is hoped that, in the future, newer anti-viral agents without the potent immunomodulating effects of interferon will be available. The apparent inability of the host to mount neutralizing antibodies suggests that development of an effective HCV will be difficult [118] .
Summary
Effective control measures to reduce the spread of HBV in dialysis units have had a major beneficial impact on the management of patients with chronic renal failure ( Table 3 ). The exact impact of chronic HBV infection on graft and patient survival following RT remains unclear, and the outcome may depend in great part on the severity of the pre-RT liver disease. RT should only be offered to HBV-infected patients after careful consideration of all the pertinent data, including results of liver biopsy. Advances in HBV vaccination may further decrease the risk of infection in patients on HD. Our understanding of HCV is evolving rapidly, but the question of the risk of transmission of HCV within dialysis units is still unsettled and thus recommendations about isolation of HCV-infected patients are not possible. Although RT does not appear to be deleterious in many HCVinfected patients, histologic and clinical evidence of severe liver disease should also prompt caution in offering RT. Longer term studies are required to assess the ultimate effect of RT in patients with HCV. Clearly, subjective improvement of quality of life associated with successful RT compared to chronic dialysis should not be withheld lightly. Pending further experience, use of organs from anti-HCV-positive donors in non-emergent situations is best avoided. The role of antiviral agents in RT recipients with chronic viral hepatitis also remains to be defined. Improved supportive care of patients with chronic renal disease, including erythropoietin therapy, as well as improved tests for anti-HCV screening of donor blood will help to further diminish exposure to HCV in HD units. 
